Novo Nordisk's Pill Approval as a Growth Catalyst

28 days ago

Louise Moon

"Nova Nordisk surging today, investors salivating because there's been a new step forward for this drug maker. Yeah, a real crucial step actually. So, they've they've won approval in the US to sell a pill version of uh Wiggoi, their their blockbuster obesity drug. So, that should start from January and it's it's at a starting price of 149 a month. But the reason it's crucial is is uh Novo essentially kind of created this whole market and then they've been struggling to keep up particularly in competition with their US rival Eli Liy. And if you look at their both of their share prices um over the past year or so, you can see a real divergence. So Eli Liy kind of shooting quite far higher and uh Novo has has had quite big losses really really this year. So they're trying to keep up. They're trying to stay competitive."

Novo Nordisk has received US approval to launch a pill version of its blockbuster obesity drug starting in January, aiming to revitalize growth amid stiff competition from its US rival Eli Liy. The commentary highlights a divergence in share performance over the past year, noting that although Novo created the market, it has lagged recently and is looking to use this launch as a growth catalyst.

Related Stocks